<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970762</url>
  </required_header>
  <id_info>
    <org_study_id>P05975</org_study_id>
    <secondary_id>71101</secondary_id>
    <nct_id>NCT00970762</nct_id>
  </id_info>
  <brief_title>Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)</brief_title>
  <official_title>Comparative Study of Org 9426 With Vecuronium Bromide (Phase III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted to determine and compare the safety and effectiveness of two
      neuromuscular blockers (rocuronium and vecuronium) at various doses in adults who are
      undergoing general elective surgery with sevoflurane anesthesia.

      Study participants received an intubating dose of a neuromuscular blocker (to enable
      insertion of a tube through the nose or mouth into the trachea to provide artificial
      ventilation). The intubating dose was followed by repeated bolus maintenance doses as needed,
      to maintain muscle relaxation. The time it takes to reach maximal effect of the neuromuscular
      blocker (onset time) after the intubating dose was measured and compared as the primary
      outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TOF Watch-SX (acceleration transducer) was used in the measurement of neuromuscular
      blocking action.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset time of intubating dose. DESCRIPTION: The time interval between the completion of injection of the study drug (rocuronium or vecuronium) and the maximal depression of first twitch--measured via TOF Watch Sx(R)-- was defined as the onset time.</measure>
    <time_frame>Day of Surgery, after injection of study drug until maximal depression of first twitch achieved</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who achieved maximal block &gt;=90% after the intubating dose. DESCRIPTION: Reaching a 90% depression of first twitch--measured via TOF Watch Sx(R)--was defined as achieving 90% block</measure>
    <time_frame>Day of Surgery, after injection of study drug until maximal depression of first twice achieved</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical duration after first maintenance dose. DESCRIPTION: The time interval between the completion of injection of study drug and return of first twitch to 25%(as measured by TOF Watch Sx(R)) was defined as the clinical duration.</measure>
    <time_frame>Day of Surgery, after injection of study drug until return of first twitch to 25%</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Rocuronium 0.6 INT, 0.1 MNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium 0.6 INT, 0.15 MNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium 0.6 INT, 0.2 MNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium 0.9 INT, 0.1 MNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium 0.9 INT, 0.15 MNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rocuronium 0.9 INT, 0.2 MNT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vecuronium 0.1 INT, 0.025 MNT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.6 mg/kg intubating dose</intervention_name>
    <description>Rocuronium 0.6 mg/kg intubating dose</description>
    <arm_group_label>Rocuronium 0.6 INT, 0.1 MNT</arm_group_label>
    <arm_group_label>Rocuronium 0.6 INT, 0.15 MNT</arm_group_label>
    <arm_group_label>Rocuronium 0.6 INT, 0.2 MNT</arm_group_label>
    <other_name>Zemuron</other_name>
    <other_name>Org 9426</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.9 mg/kg intubating dose</intervention_name>
    <description>0.9 mg/kg intubating dose of rocuronium</description>
    <arm_group_label>Rocuronium 0.9 INT, 0.1 MNT</arm_group_label>
    <arm_group_label>Rocuronium 0.9 INT, 0.15 MNT</arm_group_label>
    <arm_group_label>Rocuronium 0.9 INT, 0.2 MNT</arm_group_label>
    <other_name>Zemuron</other_name>
    <other_name>Org 9426</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.1 mg/kg maintenance dose</intervention_name>
    <description>Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.</description>
    <arm_group_label>Rocuronium 0.6 INT, 0.1 MNT</arm_group_label>
    <arm_group_label>Rocuronium 0.9 INT, 0.1 MNT</arm_group_label>
    <other_name>Zemuron</other_name>
    <other_name>Org 9426</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.15 mg/kg maintenance dose</intervention_name>
    <description>Rocuronium 0.15 mg/kg maintenance dose following the intubating dose</description>
    <arm_group_label>Rocuronium 0.6 INT, 0.15 MNT</arm_group_label>
    <arm_group_label>Rocuronium 0.9 INT, 0.15 MNT</arm_group_label>
    <other_name>Zemuron</other_name>
    <other_name>Org 9426</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium 0.2 mg/kg maintenance</intervention_name>
    <description>Rocuronium 0.2 mg/kg maintenance dose following the intubating dose</description>
    <arm_group_label>Rocuronium 0.6 INT, 0.2 MNT</arm_group_label>
    <arm_group_label>Rocuronium 0.9 INT, 0.2 MNT</arm_group_label>
    <other_name>Zemuron</other_name>
    <other_name>Org 9426</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vecuronium 0.1 mg/kg intubating dose</intervention_name>
    <description>Vecuronium 0.1 mg/kg intubating dose</description>
    <arm_group_label>Vecuronium 0.1 INT, 0.025 MNT</arm_group_label>
    <other_name>Norcuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vecuronium 0.025 mg/kg maintenance dose</intervention_name>
    <description>Vecuronium 0.025 mg/kg maintenance dose following the intubating dose</description>
    <arm_group_label>Vecuronium 0.1 INT, 0.025 MNT</arm_group_label>
    <other_name>Norcuron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  at least 20 but under 65 years of age

          -  American Society of Anesthesiologists (ASA) Class 1, 2 or 3 for general elective
             surgery

          -  not considered to be pregnant

          -  scheduled for elective surgery under sevoflurane or propofol anesthesia with an
             anticipated duration of about 1.5-3 hours

          -  normal laboratory values

        Exclusion Criteria:

          -  certain medical conditions or medical histories

          -  receiving certain medications or treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2009</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Vecuronium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

